Patient Focus

March 27, 2026 Five Things to Know about TRITON-CM & How Community Insight is Shaping the Future of ATTR- ... TRITON-CM, Alnylam's Phase 3 clinical trial evaluating nucresiran, a third-generation investigational RNAi therapeutic for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), represents one of the largest global studies ever conducted in this disease. Read More ›
October 24, 2025 Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyreti ... Enhancing understanding of this life-threatening disease and ensuring that care reflects the realities of those living with it are vital goals shared across the Read More ›
October 20, 2025 Alnylam’s Commitment to Health Literacy for All As a patient-centric organization, Alnylam is fully committed to promoting the principles of health literacy as an integral part of our innovation and culture. Read More ›
September 6, 2023 First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR Am ... The Amyloidosis Alliance has published the first-ever consensus recommendations for patient- and family-centred holistic care in ATTRv. Read More ›
February 28, 2023 The Importance of Self-Advocacy: Supporting Patients and Caregivers in Their Rare Disease ... Rare Disease Day unites the community to spread awareness and support the millions of people worldwide living with with a rare disease. Read More ›
May 9, 2022 Building a Collaborative Framework for Facilitating Patient Access to Innovative Therapies Alnylam worked with leading European economists and other healthcare experts to develop what we call the Value-Based Negotiation Framework (VBNF) to help... Read More ›
April 2, 2022 The Making of Two of Me: Living with Porphyria Cynthia Lowen, Emmy-nominated filmmaker, talks about the making of Two of Me: Living with Porphyria. Read More ›
February 28, 2022 Supporting Health Equity for All Through Leadership, Action and Partnership "Health equity" means that everyone has a fair and just opportunity to live the healthiest life possible, regardless of who they are, where they live or how... Read More ›
December 21, 2021 Alnylam Publishes 2021 Patient Access Philosophy Report Alnylam has published its 2021 Patient Access Philosophy Report detailing its actions as a company to provide access to its medicines for those who may... Read More ›
December 16, 2021 Guest Post: Creating Connections to Support the hATTR Amyloidosis Community Susanne Berglund is the Chancellor of FAMY Norrbotten, an amyloidosis patient advocacy group reflects on the importance of making connections to support... Read More ›
Subscribe to Patient Focus